NORDIC NANOVECTOR: RE MANDATORY NOTIFICATION OF TRADE - PRIMARY INSIDER

Thu, Dec 08, 2016 09:18 CET

Oslo, Norway, 8 December 2016

Reference is made to the announcement made earlier today regarding sale of shares by primary insider Jostein Dahle, and the announcement made on 6 December 2016 regarding the Company's launch of a private placement of new shares.
As stated in the launch announcement of the private placement, the Company, its board members, executive management and major shareholder have all agreed with the Joint Bookrunners to a lock-up for a period of 180 days from the closing date of the private placement, subject to customary and de minimis exceptions. Jostein Dahle's share sale was made under the de minimis exception and was conducted to finance personal obligations.

Tags:

Cancer Therapy non-hodgkins lymphoma Betalutin Nordic Nanovector Radioimmunotherapy Roy Hartvig Larsen anticancer therapeutics

NORDIC NANOVECTOR: RE MANDATORY NOTIFICATION OF TRADE - PRIMARY INSIDER

Subscribe